CN112603902A - Dexketoprofen trometamol capsule and preparation process thereof - Google Patents
Dexketoprofen trometamol capsule and preparation process thereof Download PDFInfo
- Publication number
- CN112603902A CN112603902A CN202011438831.9A CN202011438831A CN112603902A CN 112603902 A CN112603902 A CN 112603902A CN 202011438831 A CN202011438831 A CN 202011438831A CN 112603902 A CN112603902 A CN 112603902A
- Authority
- CN
- China
- Prior art keywords
- mixing
- dexketoprofen
- capsule
- magnesium stearate
- spraying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QUZMDHVOUNDEKW-MERQFXBCSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;(2s)-2-(3-benzoylphenyl)propanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 QUZMDHVOUNDEKW-MERQFXBCSA-N 0.000 title claims abstract description 26
- 239000002775 capsule Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229960005448 dexketoprofen trometamol Drugs 0.000 title claims description 13
- 238000002156 mixing Methods 0.000 claims abstract description 28
- 239000008187 granular material Substances 0.000 claims abstract description 11
- 238000005070 sampling Methods 0.000 claims abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 12
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 229920000881 Modified starch Polymers 0.000 claims description 9
- 238000005243 fluidization Methods 0.000 claims description 9
- 238000011068 loading method Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims 2
- 235000012222 talc Nutrition 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000202 analgesic effect Effects 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000003533 narcotic effect Effects 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a dexketoprofen tromethamine capsule which is characterized by consisting of the following components in parts by weight: the preparation method comprises the following steps of mixing, granulating, finishing granules, totally mixing, sampling and inspecting to obtain a finished product. Compared with the prior art, the invention has the advantages that: quick action, better analgesic effect and less side effect.
Description
Technical Field
The invention relates to the technical field of capsule medicines, in particular to a dexketoprofen tromethamine capsule and a preparation process thereof.
Background
Dexketoprofen trometamol is used for all pains and is suitable for eliminating pains caused by wounds, postoperative pains, gall, sharp pains and various reasons in a short time. The tablet or injection can be used for relieving moderate to severe postoperative pain, including abdominal, thoracic, gynecological, oral, orthopedic and urological operations. In addition, the medicine can also relieve acute renal glue pain, biliary colic, toothache, wound pain, trigeminal neuralgia, cancer visceral pain and various pains which can be achieved only by using morphine or pethidine.
Moderate pain is a common clinical symptom, patients have a large amount, such as various postoperative pain, cancer pain and the like, in the case of the moderate pain, the analgesic effect of nonsteroidal anti-inflammatory analgesic drugs is not enough, narcotic analgesics are usually needed, but the narcotic analgesics are easy to generate dependence because of repeated administration. In clinical analgesia, two types of analgesics are usually combined to enhance the analgesic effect and reduce the dosage of narcotic analgesics, especially the dosage of strong dependence drugs such as morphine and the like.
Disclosure of Invention
The invention aims to solve the problems in the prior art, and further provides a dexketoprofen tromethamine capsule which has the advantages of quick response, better analgesic effect and small side effect, and a preparation process thereof.
The purpose of the invention is realized by the following technical scheme:
the dexketoprofen trometamol capsule consists of the following components in percentage by weight: 3.7 parts of dexketoprofen trometamol, 6 parts of pregelatinized starch, 14 parts of microcrystalline cellulose, 1 part of hydroxypropyl methyl cellulose, and a proper amount of magnesium stearate, talcum powder and 30% ethanol.
Further, the weight ratio of the magnesium stearate to the talcum powder is 1:6, and the mixing weight of the magnesium stearate and the talcum powder is equal to the mixing weight of the dexketoprofen tromethamine, the pregelatinized starch, the microcrystalline cellulose and the hydroxypropyl methyl cellulose.
The preparation process of the dexketoprofen tromethamine capsule comprises the following steps:
step one, mixing: starting a multifunctional fluidized granulation coating machine, preheating a pot body, placing dexketoprofen trometamol, pregelatinized starch, microcrystalline cellulose and hydroxypropyl methylcellulose which are weighed according to the weight ratio into the multifunctional fluidized granulation coating machine, setting the temperature to be 75-90 ℃, starting a fan, setting the induced air frequency of the fan to be 20-30 Hz, boiling and mixing the fine powder, and mixing for 10 minutes;
step two, granulation: when the air outlet temperature rises to 40-55 ℃, spraying by using 30% ethanol, controlling the frequency of an induced draft fan at 20-40 Hz, controlling the speed of a peristaltic pump at 30-50 r/min, observing the boiling fluidization state of the material in the spraying process, stopping spraying when the boiling fluidization state of the material is slow, drying, spraying again when the boiling fluidization state of the material is good, alternately performing the process until the granulation is finished, stopping spraying after the granulation is finished, and continuously drying for 20-40 minutes until the moisture content of the particles is less than or equal to 6%;
step three, granule finishing: after drying, finishing the particles by using a ternary rotary vibration sieve, mounting a 24-mesh screen on the ternary rotary vibration sieve, and putting the particles smaller than 24 meshes into a clean container for sealing and storing;
step four, total mixing: taking the sized dexketoprofen tromethamine granules, magnesium stearate and talcum powder, adopting an equivalent incremental method, firstly taking a proper amount of magnesium stearate and talcum powder to mix for five minutes, weighing equivalent dexketoprofen tromethamine granules after mixing, adding into the mixture and mixing for 5 minutes; by analogy, adding the rest particles into the mixture until the weight of the mixture is 10% of that of all the materials, mixing, and filling the total mixed powder into a clean container for sealed storage after the mixture is finished;
step six, sampling inspection; sampling and detecting the content;
step seven, finished product: loading into No. 3 capsule according to the loading requirement, wherein the loading of the capsule is 110mg-130 mg.
Compared with the prior art, the invention has the advantages that:
the traditional Chinese medicine composition has the main effects of diminishing inflammation and easing pain, can be used for treating osteoarthritis, ankylosing spondylitis, gouty arthritis and rheumatoid arthritis, has a certain relieving effect on postoperative pain, cancer pain, toothache and abdominal pain during menstruation, has a certain auxiliary effect on treating general pain caused by cold and fever, and can quickly take effect, achieve a better analgesic effect and reduce side effects.
The function of each auxiliary material in the prescription is as follows:
microcrystalline cellulose: as a disintegrant, filler;
compressible starch: the fluidity is good, and the difference is small after the capsule is filled;
hydroxypropyl methylcellulose: as a binder;
talc powder: the function of fluidity is achieved;
magnesium stearate: and acts as a lubricant.
Detailed Description
The amount of the needed dexketoprofen tromethamine is calculated according to the following formula: the raw material x (1-loss on drying) x content was calculated to be 3.7kg, and then pregelatinized starch was weighed in order: 6.0kg, microcrystalline cellulose: 14.0kg, hypromellose: 1.0kg, then dividing the above components into 8 parts, namely, each part of dexketoprofen trometamol: 462.5g, pregelatinized starch: 0.75kg, microcrystalline cellulose: 1.75kg, hypromellose: 0.125 kg; preparing a proper amount of the components with the weight ratio of 1:6 magnesium stearate and talcum powder, and a proper amount of 30% ethanol.
The preparation process comprises the following steps:
step one, mixing: starting a multifunctional fluidized granulation coating machine, preheating a pot body, putting the separated dexketoprofen trometamol, pregelatinized starch, microcrystalline cellulose and hydroxypropyl methylcellulose into the multifunctional fluidized granulation coating machine, setting the temperature to be 75-90 ℃, starting a fan, setting the induced air frequency of the fan to be 20-30 Hz, boiling and mixing the fine powder, and mixing for 10 minutes;
step two, granulation: when the air outlet temperature rises to 40-55 ℃, spraying by using 30% ethanol, controlling the frequency of an induced draft fan at 20-40 Hz, controlling the speed of a peristaltic pump at 30-50 r/min, observing the boiling fluidization state of the material in the spraying process, stopping spraying when the boiling fluidization state of the material is slow, drying, spraying again when the boiling fluidization state of the material is good, alternately performing the process until the granulation is finished, stopping spraying after the granulation is finished, and continuously drying for 20-40 minutes until the moisture content of the particles is less than or equal to 6%;
step three, granule finishing: after drying, finishing the particles by using a ternary rotary vibration sieve, mounting a 24-mesh screen on the ternary rotary vibration sieve, and putting the particles smaller than 24 meshes into a clean container for sealing and storing;
step four, total mixing: taking the sized dexketoprofen tromethamine granules, 0.1kg of magnesium stearate and 0.6kg of talcum powder, firstly mixing the magnesium stearate and the talcum powder for five minutes by adopting an equivalent incremental method, weighing equivalent dexketoprofen tromethamine granules after mixing, adding the granules into the mixture, and mixing for 5 minutes; by analogy, adding the rest particles into the mixture until the weight of the mixture is 10% of that of all the materials, mixing, and filling the total mixed powder into a clean container for sealed storage after the mixture is finished;
step six, sampling inspection; sampling and detecting the content;
step seven, finished product: loading into No. 3 capsule according to the loading requirement, wherein the loading of the capsule is 110mg-130 mg.
Claims (3)
1. The dexketoprofen trometamol capsule is characterized by consisting of the following components in parts by weight: 3.7 parts of dexketoprofen trometamol, 6 parts of pregelatinized starch, 14 parts of microcrystalline cellulose, 1 part of hydroxypropyl methyl cellulose, and a proper amount of magnesium stearate, talcum powder and 30% ethanol.
2. The dexketoprofen trometamol capsule according to claim 1, wherein the weight ratio of magnesium stearate to talc is 1:6, and the mixing weight of magnesium stearate and talc is equal to the mixing weight of dexketoprofen trometamol, pregelatinized starch, microcrystalline cellulose and hydroxypropyl methyl cellulose.
3. The preparation process of the dexketoprofen tromethamine capsule is characterized by comprising the following steps of:
step one, mixing: starting a multifunctional fluidized granulation coating machine, preheating a pot body, placing dexketoprofen trometamol, pregelatinized starch, microcrystalline cellulose and hydroxypropyl methylcellulose which are weighed according to the weight ratio into the multifunctional fluidized granulation coating machine, setting the temperature to be 75-90 ℃, starting a fan, setting the induced air frequency of the fan to be 20-30 Hz, boiling and mixing the fine powder, and mixing for 10 minutes;
step two, granulation: when the air outlet temperature rises to 40-55 ℃, spraying by using 30% ethanol, controlling the frequency of an induced draft fan at 20-40 Hz, controlling the speed of a peristaltic pump at 30-50 r/min, observing the boiling fluidization state of the material in the spraying process, stopping spraying when the boiling fluidization state of the material is slow, drying, spraying again when the boiling fluidization state of the material is good, alternately performing the process until the granulation is finished, stopping spraying after the granulation is finished, and continuously drying for 20-40 minutes until the moisture content of the particles is less than or equal to 6%;
step three, granule finishing: after drying, finishing the particles by using a ternary rotary vibration sieve, mounting a 24-mesh screen on the ternary rotary vibration sieve, and putting the particles smaller than 24 meshes into a clean container for sealing and storing;
step four, total mixing: taking the sized dexketoprofen tromethamine granules, magnesium stearate and talcum powder, adopting an equivalent incremental method, firstly taking a proper amount of magnesium stearate and talcum powder to mix for five minutes, weighing equivalent dexketoprofen tromethamine granules after mixing, adding into the mixture and mixing for 5 minutes; by analogy, adding the rest particles into the mixture until the weight of the mixture is 10% of that of all the materials, mixing, and filling the total mixed powder into a clean container for sealed storage after the mixture is finished;
step six, sampling inspection; sampling and detecting the content;
step seven, finished product: loading into No. 3 capsule according to the loading requirement, wherein the loading of the capsule is 110mg-130 mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011438831.9A CN112603902A (en) | 2020-12-07 | 2020-12-07 | Dexketoprofen trometamol capsule and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011438831.9A CN112603902A (en) | 2020-12-07 | 2020-12-07 | Dexketoprofen trometamol capsule and preparation process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112603902A true CN112603902A (en) | 2021-04-06 |
Family
ID=75232915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011438831.9A Pending CN112603902A (en) | 2020-12-07 | 2020-12-07 | Dexketoprofen trometamol capsule and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112603902A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114864906A (en) * | 2022-05-31 | 2022-08-05 | 焦作熔创石墨科技有限公司 | Carbon cathode material of lithium ion battery and preparation method and system thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013182609A1 (en) * | 2012-06-06 | 2013-12-12 | Galenicum Health S.L. | Stable pharmaceutical compositions with a fast onset |
| CN104188947A (en) * | 2014-08-26 | 2014-12-10 | 安徽省逸欣铭医药科技有限公司 | Compound pharmaceutical composition of tapentadol hydrochloride and dexketoprofen trometamol |
-
2020
- 2020-12-07 CN CN202011438831.9A patent/CN112603902A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013182609A1 (en) * | 2012-06-06 | 2013-12-12 | Galenicum Health S.L. | Stable pharmaceutical compositions with a fast onset |
| CN104188947A (en) * | 2014-08-26 | 2014-12-10 | 安徽省逸欣铭医药科技有限公司 | Compound pharmaceutical composition of tapentadol hydrochloride and dexketoprofen trometamol |
Non-Patent Citations (1)
| Title |
|---|
| 郑超华等: "复方伤痛胶囊治疗腰肌劳损56例疗效观察", 《河北中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114864906A (en) * | 2022-05-31 | 2022-08-05 | 焦作熔创石墨科技有限公司 | Carbon cathode material of lithium ion battery and preparation method and system thereof |
| CN114864906B (en) * | 2022-05-31 | 2023-11-21 | 焦作熔创石墨科技有限公司 | Lithium ion battery carbon negative electrode material, and preparation method and system thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO138683B (en) | BASIC FOR USE IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF THE ACTIVE INGREDIENT | |
| CN112494440B (en) | Sitagliptin phosphate tablet and preparation method thereof | |
| CN112603902A (en) | Dexketoprofen trometamol capsule and preparation process thereof | |
| CN111297818B (en) | High-drug-loading-capacity piracetam tablet composition and preparation method thereof | |
| CN105434386B (en) | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof | |
| JP2019516706A (en) | Novel crystalline form of dapagliflozin and method for producing and use thereof | |
| CN111012752B (en) | Letrozole tablet and preparation method thereof | |
| CN107412198A (en) | Duloxetine hydrochloride enteric slow release granule and preparation method thereof | |
| CN105395507B (en) | A kind of cyclobenzaprine hydrochloride sustained release tablets | |
| CN108836973B (en) | Metformin-glibenclamide capsule and preparation method thereof | |
| CN110638780A (en) | Nefopam hydrochloride tablet and preparation method thereof | |
| CN107375938B (en) | Glucosamine hydrochloride adhesive, tablets and preparation method thereof | |
| CN101756939A (en) | Dexketoprofen coating sustained-release micro-encapsulated capsule | |
| CN112741827B (en) | Vigabatrin solid preparation and preparation method thereof | |
| CN103989643B (en) | Tablet containing ramelteon and copolyvidone | |
| CN106620644A (en) | Stable perindopril indapamide tablet and preparation technology | |
| CN108578404B (en) | Medicinal composition containing irbesartan and amlodipine and preparation method thereof | |
| CN101773537A (en) | Slow-release microspheres prepared from active ingredients of tripterygium wilfordii and preparation method thereof | |
| CN101756938B (en) | Ketorolac tromethamine capsule and preparation method thereof | |
| CN108434110B (en) | Misoprostol composition, tablet and application thereof | |
| CN113521067B (en) | Famotidine zinc gluconate preparation composition and preparation method thereof | |
| CN108938587A (en) | A kind of Sustained Release Tablets of Diclofenac Sodium And Its and preparation method thereof | |
| CN102247369B (en) | Compound naproxen esomeprazole medicine composition and preparation method thereof | |
| WO2005105095A1 (en) | The combination for treating hyperlipemia | |
| CN112220787A (en) | Olmesartan medoxomil amlodipine tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210406 |